{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:33:34Z","timestamp":1787009614528,"version":"build-2736575974"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"SI2","license":[{"start":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Mass vaccination is the most effective strategy for controlling the COVID-19 pandemic. This study aimed to evaluate the 6-month immunogenicity after BNT162b2-COVID-19 vaccination in adolescents with JIA on TNFi treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-centre study included adolescents with JIA treated with TNFi for at least 18\u2009months. Patients received two doses of COVID-19 vaccine (Pfizer-BioNTech) from 15 April to 15 May 2021. Quantitative measurement of IgG antibodies to SARS-CoV-2-spike-protein-1 was performed at 1, 3 and 6\u2009months post-vaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 21 adolescents with JIA in clinical remission at the time of vaccinations were enrolled. None of them discontinued TNFi\/MTX treatment at the time of vaccine administration or during the follow-up period. All patients developed a sustained humoral response against SARS-CoV-2 at 1 and 3\u2009months after vaccination (P\u2009&amp;lt;\u20090.05). The antibody levels decreased significantly at 6\u2009months post-vaccination (P\u2009&amp;lt;\u20090.01). The type of JIA did not reveal any differences in the humoral response at 3 (P\u2009=\u20090.894) or 6\u2009months post-vaccination (P\u2009=\u20090.72). No difference was detected upon comparison of the immunogenicity between the different treatment arms (adalimumab vs etanercept) at 3 (P\u2009=\u20090.387) and 6\u2009months (P\u2009=\u20090.526), or TNFi monotherapy vs combined therapy (TNFi plus methotrexate) at 3 (P\u2009=\u20090.623) and 6\u2009months (P\u2009=\u20090.885).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although mRNA vaccines develop satisfactory immunogenicity at 1 month and 3 months post-vaccination in adolescents with JIA on TNFi, SARS-CoV-2 antibody titres decrease significantly overtime, remaining at lower levels at 6\u2009months. Further collaborative studies are required to determine long-term immunogenicity, real duration of immune protection and the need for a booster vaccine dose.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keac352","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T09:46:53Z","timestamp":1657014413000},"page":"SI205-SI209","source":"Crossref","is-referenced-by-count":3,"title":["Immunogenicity 6 months post COVID-19 mRNA vaccination among adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors"],"prefix":"10.1093","volume":"62","author":[{"given":"Dimitra","family":"Dimopoulou","sequence":"first","affiliation":[{"name":"Infectious Diseases, Immunology and Rheumatology Unit, Second Department of Paediatrics, \u2018P. & A. Kyriakou\u2019 Children's Hospital, National and Kapodistrian University of Athens , Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria N","family":"Tsolia","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Immunology and Rheumatology Unit, Second Department of Paediatrics, \u2018P. & A. Kyriakou\u2019 Children's Hospital, National and Kapodistrian University of Athens , Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikos","family":"Spyridis","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Immunology and Rheumatology Unit, Second Department of Paediatrics, \u2018P. & A. Kyriakou\u2019 Children's Hospital, National and Kapodistrian University of Athens , Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despoina N","family":"Maritsi","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Immunology and Rheumatology Unit, Second Department of Paediatrics, \u2018P. & A. Kyriakou\u2019 Children's Hospital, National and Kapodistrian University of Athens , Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,7,5]]},"reference":[{"key":"2023022318582524800_","doi-asserted-by":"crossref","first-page":"e001896","DOI":"10.1136\/rmdopen-2021-001896","article-title":"TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD","volume":"7","author":"Regierer","year":"2021","journal-title":"RMD Open"},{"key":"2023022318582524800_","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keac089","article-title":"Humoral and cellular response to COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases under real-life conditions","volume":"61","author":"Krasselt","year":"2022","journal-title":"Rheumatology"},{"key":"2023022318582524800_","author":"European Centre for Disease Prevention and Control (ECDC)","year":"9 2021"},{"key":"2023022318582524800_","doi-asserted-by":"crossref","first-page":"102927","DOI":"10.1016\/j.autrev.2021.102927","article-title":"Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: systematic review and meta-analysis","volume":"21","author":"Jena","year":"2022","journal-title":"Autoimmun Rev"},{"key":"2023022318582524800_","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/annrheumdis-2021-220597","article-title":"Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease","volume":"80","author":"Haberman","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2023022318582524800_","doi-asserted-by":"crossref","first-page":"e001594","DOI":"10.1136\/rmdopen-2021-001594","article-title":"Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases","volume":"7","author":"Furer","year":"2021","journal-title":"RMD Open"},{"key":"2023022318582524800_","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/art.41977","article-title":"Safety and tolerability of the COVID-19 messenger RNA vaccine in adolescents with juvenile idiopathic arthritis treated with tumor necrosis factor inhibitors","volume":"74","author":"Dimopoulou","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2023022318582524800_","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1136\/annrheumdis-2021-221607","article-title":"Immunogenicity of the COVID-19 mRNA vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors","volume":"81","author":"Dimopoulou","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2023022318582524800_","first-page":"390","article-title":"International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"2023022318582524800_","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/art.41879","article-title":"Definition and validation of the American college of rheumatology 2021 juvenile arthritis disease activity score cutoffs for disease activity states in Juvenile Idiopathic Arthritis","volume":"73","author":"Trincianti","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2023022318582524800_","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1136\/annrheumdis-2021-220862","article-title":"Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis","volume":"80","author":"Bugatti","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2023022318582524800_","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S2665-9913(21)00333-7","article-title":"Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study","volume":"4","author":"Mahil","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"2023022318582524800_","author":"Centers for Disease Control and Prevention (CDC)"},{"key":"2023022318582524800_","doi-asserted-by":"crossref","first-page":"e002008","DOI":"10.1136\/rmdopen-2021-002008","article-title":"Humoral protection to SARS-CoV2 declines faster in patients on TNF alpha blocking therapies","volume":"7","author":"Geisen","year":"2021","journal-title":"RMD Open"},{"key":"2023022318582524800_","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/S2665-9913(21)00394-5","article-title":"Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study","volume":"4","author":"Jyssum","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"2023022318582524800_","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/08830185.2021.1883600","article-title":"COVID-19: immunology, immunopathogenesis and potential therapies","volume":"41","author":"Bhardwaj","year":"2022","journal-title":"Int Rev Immunol"},{"key":"2023022318582524800_","doi-asserted-by":"crossref","DOI":"10.1136\/bmjspcare-2021-003371","article-title":"COVID-19 vaccination and immunomodulatory or immunosuppressive drugs: indications and contraindications","author":"Pathania","year":"2021","journal-title":"BMJ Support Palliat Care"},{"key":"2023022318582524800_","doi-asserted-by":"crossref","first-page":"annrheumdis-2018-213222","DOI":"10.1136\/annrheumdis-2018-213222","article-title":"Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial","volume":"77","author":"Park","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2023022318582524800_","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1136\/annrheumdis-2021-220541","article-title":"Correspondence on \u2018EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs\u2019","volume":"80","author":"Bugatti","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2023022318582524800_","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1016\/S2665-9913(21)00108-9","article-title":"Flare of rheumatoid arthritis after COVID-19 vaccination","volume":"3","author":"Terracina","year":"2021","journal-title":"Lancet Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keac352\/44551926\/keac352.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/SI2\/SI205\/49318825\/keac352.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/SI2\/SI205\/49318825\/keac352.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T00:41:35Z","timestamp":1700786495000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/62\/SI2\/SI205\/6631220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,5]]},"references-count":20,"journal-issue":{"issue":"SI2","published-online":{"date-parts":[[2022,7,5]]},"published-print":{"date-parts":[[2023,2,23]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keac352","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,1]]},"published":{"date-parts":[[2022,7,5]]}}}